Anabolic treatment for osteoporosis and fragility fracture risk: one year in review 2024.
Clin Exp Rheumatol
; 42(7): 1311-1316, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-39026507
ABSTRACT
Osteoporosis is a skeletal disease characterised by reduced bone mass and deterioration of bone microarchitecture, underlying a higher risk of fragility fractures. Several options are available for its treatment, including both anti-resorptive and anabolic agents. The present review discusses and summarises the most recent literature on anabolic treatment, with a focus on abaloparatide, and on the assessment of fragility fracture risk, with a focus on trabecular bone score. Finally, we provide a discussion on the effects of different antiosteoporotic medications in terms of fragility fracture risk reduction.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Osteoporose
/
Densidade Óssea
/
Conservadores da Densidade Óssea
/
Fraturas por Osteoporose
/
Anabolizantes
Limite:
Humans
Idioma:
En
Revista:
Clin Exp Rheumatol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Itália
País de publicação:
Itália